Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04793867 · ClinicalTrials.gov registry record
Regional Phenotyping of CF and Non-CF Bronchiectasis
A clinical trial of Cystic Fibrosis and Non-CF Bronchiectasis, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT04793867: Recruiting study of Cystic Fibrosis and Non-CF Bronchiectasis, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT04793867 is a study of Cystic Fibrosis and Non-CF Bronchiectasis that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 100 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (44% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04793867, a study of Cystic Fibrosis and Non-CF Bronchiectasis, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The Investigators propose to study pediatric subjects who are diagnosed with cystic fibrosis (CF) and patients with non-CF bronchiectasis, with the goal of developing markers of CF lung disease severity, progression, and therapy response. The Investigator's central hypothesis is that image-based markers can forecast pathophysiology prior to spirometric changes.
Primary Outcome
Quantify the measurement agreement between the ventilated volume of CF and Non-CF Bronchiectasis lungs vs healthy lungs
Conditions Studied
Interventions
- DRUG Xenon
Study Locations (1)
Ohio
- Penny New - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-02-08 |
| Est. Completion | 2027-03-31 |
What NCT04793867 shows while recruiting
NCT04793867 is an observational study that tracks outcomes without assigning an intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (44% lower).
The record links to 2 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Xenon is the first listed.
NCT04793867 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT04793867 about?
NCT04793867 is a clinical study titled "Regional Phenotyping of CF and Non-CF Bronchiectasis". The Investigators propose to study pediatric subjects who are diagnosed with cystic fibrosis (CF) and patients with non-CF bronchiectasis, with the goal of developing markers of CF lung disease severity, progression, and therapy response. The Investigator's central hypothesis is that image-based mar...
What is the current status of trial NCT04793867?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2021-02-08. Estimated completion is 2027-03-31.
What conditions does trial NCT04793867 study?
This clinical trial studies the following conditions: Cystic Fibrosis, Non-CF Bronchiectasis.
What interventions are being tested in trial NCT04793867?
The interventions under investigation include: Xenon (DRUG).
Who is sponsoring clinical trial NCT04793867?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04793867 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04793867's enrollment target sits among peer trials
100 60th of 169 higher than 107 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Exercise in Child Health
RECRUITING · NA
-
Targeting Inflammation With Losartan to Improve Response to Modulator Therapy in Cystic Fibrosis.
RECRUITING · Phase 2
-
A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis
RECRUITING · NA
-
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
RECRUITING
-
Assessing Tenapanor as a Treatment of CF-related Constipation.
RECRUITING · Phase 3
-
Genetics of Insulin and Incretins in Cystic Fibrosis
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI